Classifications: immunosuppressant; antiinflammatory; disease-modifiying rheumatic drug (dmard); Therapeutic:immunosuppressant; antiinflammatory; antirheumatic; dmard
Pregnancy Category: D
25 mg, 50 mg, 75 mg, 100 mg tablets; 100 mg vial
Antagonizes purine metabolism and appears to inhibit DNA, RNA, and normal protein synthesis in rapidly growing cells.
Suppresses T cell effects before transplant rejection. Has immunosuppressant and antiinflammatory properties.
Adjunctive agent to prevent rejection of kidney allografts, usually with other immunosuppressants. Also used in selective
adult patients with severe, active rheumatoid arthritis; unresponsive to conventional therapy.
SLE, lupus nephritis, psoriatic arthritis; ulcerative colitis, pemphigus, nephrotic syndrome, and other inflammatory and
Hypersensitivity to azathioprine or mercaptopurine; clinically active infection, immunization of patient or close family
members with live virus vaccines; anuria; pancreatitis; patients receiving alkylating agents (increased risk of neoplasms),
concurrent radiation therapy; pregnancy (category D), lactation.
Impaired kidney and liver function; patients receiving cadaver kidney; myasthenia gravis.
Route & Dosage
Adult: PO 35 mg/kg/d initially, may be able to reduce to 13 mg/kg/d IV 35 mg/kg/d initially, may be able to reduce to 13 mg/kg/d; transfer to PO
Adult: PO 1 mg/kg/d initially, may be increased by 0.5 mg/kg/d at 46 wk intervals if needed up to 2.5 mg/kg/d
Doses calculated on IBW.
Clcr 1050 mL/min: 75% of usual dose; <10 mL/min: 50% of usual dose
Hemodialysis: Administer after dialysis
- Give oral drug in divided doses (as prescribed) with food or immediately after meals to minimize gastric disturbances.
PREPARE: Direct/Intermittent: Reconstitute by adding 10 mL sterile water for injection into vial; swirl until dissolved. May be given as prepared or further
diluted with 50 mL NS, D5W, or D5/NS. Reconstituted solution may be stored at room temperature but must be used within 24
h after reconstitution (contains no preservatives).
ADMINISTER: Direct/Intermittent: May infuse over 30 min to 8 h. Typical infusion time is 3060 min or longer. If longer infusion time is ordered, the
final volume of the IV solution is increased appropriately. Check with physician.
- Store at 15°30° C (59°86° F) in tightly closed, light-resistant containers unless otherwise
Adverse Effects (≥1%)Body as a Whole:
Hypersensitivity (skin eruptions, rash, arthralgia). GI:
Nausea, vomiting, anorexia, esophagitis, diarrhea, steatorrhea, hepatitis with elevations in bilirubin, alkaline phosphatase,
AST, ALT, biliary stasis, toxic hepatitis. Hematologic: Bone marrow depression,
thrombocytopenia, leukopenia, anemia, agranulocytosis,
pancytopenia. Other: Secondary infection (immunosuppression);
dysarthria, alopecia; carcinogenic and teratogenic potential reported.
Diagnostic Test Interference
Azathioprine may decrease plasma and urinary uric acid in patients with gout.
increases effects and toxicity of azathioprine
by reducing metabolism
of the active metabolite; allopurinol
doses should be decreased by one third or one fourth; tubocurarine
and other nondepolarizing skeletal muscle relaxants
may reverse or inhibit neuromuscular blocking effects.
Readily from GI tract. Distribution:
Crosses placenta. Metabolism:
Extensively in liver to active metabolite mercaptopurine. Elimination:
In urine. Half-Life:
Assessment & Drug Effects
- Monitor therapeutic effectiveness which usually requires 68 wk of therapy for patients with rheumatoid arthritis (improvement
in morning stiffness and grip strength). If no improvement has occurred after 12-wk trial period, drug is generally discontinued.
- Lab tests: Perform CBC, including Hgb and platelet counts, prior to and at least weekly during first month of therapy, twice
monthly during second and third months, and monthly, or more frequently thereafter, if indicated (e.g., by dosage or therapy
- Monitor for toxicity. Drug has a high toxic potential. Because it may have delayed action, dosage should be reduced or drug
withdrawn at the first indication of an abnormally large or persistent decrease in leukocyte or platelet count to avoid irreversible
bone marrow depression.
- Monitor vital signs. Report signs of infection.
- Monitor kidney function (urine protein, urine electrolytes, creatinine clearance, serum creatinine, BUN) periodically.
- Monitor I&O ratio; note color, character, and specific gravity of urine. Report an abrupt decrease in urinary output or
any change in I&O ratio.
- Monitor liver function (alkaline phosphatase, AST, ALT, serum bilirubin) and repeat at least every 3 mo or more frequently
if indicated. If hepatic toxicity (see Appendix F) develops, therapy may have to be withdrawn.
- Monitor for signs of abnormal bleeding [easy bruising, bleeding gums, petechiae, purpura, melena, epistaxis, dark urine
(hematuria), hemoptysis, hematemesis]. If thrombocytopenia occurs, invasive procedures should be withheld, if possible.
- Use protective isolation for the hospitalized patient to reduce risk of infections.
Patient & Family Education
- Avoid contact with anyone who has a cold or other infection and report signs of impending infection. Exercise scrupulous
personal hygiene because infection is a constant hazard of immunosuppressive therapy.
- Practice birth control during therapy and for 4 mo after drug is discontinued. This drug is associated with potential hazards
- Do not receive/take vaccinations or other immunity-conferring agents during therapy because they may precipitate unusually
severe reactions due to the immunosuppressive effects of the drug.